Surgical robotics — semi-autonomous procedures
176 evidence items
Surgical robots that perform portions of procedures autonomously under surgeon supervision. Includes autonomous suturing and tissue manipulation; distinct from surgeon-assisted systems which augment rather than autonomously perform. Scope covers ML/AI-driven approaches; prior deterministic or rules-based automation is out of scope.
Overview
Semi-autonomous surgical robotics hands discrete parts of an operation, such as suturing, retraction, resection and debridement, to a learned controller while the surgeon supervises rather than steers. It matters because it would turn robots from precision instruments into collaborators, but today it is a bleeding-edge practice, steady: laboratory, phantom and cadaver results keep improving, yet independent reviews agree that autonomous tissue work has not reached patients. The systems that do ship commercially automate adjacent functions like camera positioning or energy dosing, and are easily mistaken for the real thing. The deciding tension is in-human evidence, not engineering. Until several organisations show supervised autonomy succeeding in live surgery, while earning public and regulatory trust, it cannot move up.
Current Landscape
Moon Surgical's Maestro remains the most visible commercial system in this practice, and even it is positioned cautiously. An equity review in OAE Publishing describes Maestro as a laparoscopic assistant model that is not fully autonomous. KARL STORZ has expanded its surgical robotics ecosystem through a partnership with Moon Surgical. NextInSurgery counts two of the five layers in Intuitive's AI roadmap as actually live.
Other vendors are moving towards autonomy-capable platforms. Andromeda Surgical raised a $15 million Series A for semi-autonomous HoLEP. LEM Surgical announced a second FDA 510(k) clearance for its Dynamis humanoid robotic surgical system. MedBot's Toumai gained an EU CE mark after a remote prostate surgery. An incisionless Korean surgical robot cleared the FDA and signed an exclusive Olympus deal. Commercial risk is real: J&J OTTAVA FDA approval was reported alongside Vicarious Surgical's liquidation.
The strongest new autonomy result is in soft-tissue oncology, though only in phantoms. Researchers working on occupancy network-guided partial nephrectomy describe the first vision-guided autonomous system to perform complete tumour resections. In patient-derived hydrogel phantoms, their robot performed eight consecutive autonomous resections comprising 77 electrosurgical cuts. All cuts achieved negative surgical margins, with a mean absolute margin error of 1.61 ± 0.48 mm. The authors frame this as a foundation for supervised autonomous tumour removal and claim no in-human validation.
Subtask autonomy on research platforms keeps outperforming learned baselines. The MACAW system autonomously removes tissue fragments for debridement on the da Vinci Research Kit, using a single monocular camera. Its authors report a 93% success rate at 304 fragments per hour across 100 physical trials, ahead of the ACT, Diffusion Policy, π0 and π0.5 baselines. A bimanual set-up held 92% success at 473 fragments per hour. Related work applies imitation learning to suture following in open surgery and trajectory divergence monitoring to dual-arm subtasks.
General-purpose humanoid hardware has entered surgical experiments. Researchers teleoperated humanoid robots in a first-of-its-kind surgery. Humanoid robots have also completed the first gallbladder removals in pigs. The hardware carries its own barrier: the Pentagon has flagged it as Chinese military technology. A separate framework proposes staged integration of embodied AI in the operating room rather than early autonomy.
No autonomous procedure has yet been performed in a human, according to a Journal of Robotic Surgery review of autonomous surgery and world models. The review credits supervised task automation in bowel anastomosis and self-correcting ex vivo cholecystectomy clipping and cutting. It finds that state-of-the-art generative models produce photorealistic but causally and strategically implausible surgical futures. Its authors argue that translation depends on prospective evaluation, defined stopping rules and clear accountability. More broadly, only 3 of 1,357 cleared AI medical devices were tested on patient outcomes.
Reviews of image-guided specialties also place autonomy at the research stage. A Frontiers in Robotics and AI review of 48 publications and five FDA records on spinal robots finds only a small group of research systems performing constrained tasks such as K-wire insertion under supervision. It concludes that these robots should currently be understood as surgeon-controlled enabling technologies. A Journal of Robotic Surgery review of robot-assisted seed brachytherapy finds that each control layer has advanced, but none has reached the threshold for clinical deployment.
Learned control remains fragile. Studies of adversarial attacks on learned surgical policies, and of overcoming imperfect kinematics through sim-to-real visuomotor learning, show that reliability is still a research problem. Recalls by Intuitive Surgical have put da Vinci reliability in focus. Outcome data for robotic surgery offer no cover either: robotic-assisted bariatric surgery is not associated with improved patient safety.
Regulators, payers and professional bodies are starting to address autonomy explicitly. South Korea has released regulatory guidelines for automated surgical robot systems. The FDA has outlined considerations for generative-AI-enabled medical devices. HHS says trust, not technology, is the barrier to AI in clinical care. A SAGES white paper addresses risk and liability in deploying AI systems for surgery. CMS's 2026 final rule proposal gives clinical AI a payment lane.
Public trust and access further limit adoption. A UAE survey of 508 adults found that 85% had heard of robotic-assisted surgery. Their acceptance turned on trust, perceived safety and concerns about machine autonomy and loss of human control. The OAE Publishing equity review estimates that 5 billion people lack access to safe and affordable surgical care. Broader adoption is held back by the absence of any in-human autonomous procedure, missing outcome trials, undefined liability and fragile learned policies.
Tier History
Evidence (176)
— Negative: an independent review states no autonomous procedure has yet been performed in a human, and finds that surgical world models produce causally implausible futures.
— In phantoms, a vision-guided autonomous system completed 8 consecutive tumour resections (77 cuts), all margin-negative. It moves supervised soft-tissue autonomy beyond organ surfaces, but not yet into humans.
— Negative: in a UAE survey, 85% of respondents were aware of robotic surgery. Acceptance turned on trust, perceived safety and fears about machine autonomy, which points to a public-trust barrier.
— Negative: a review of 48 papers and 5 FDA records finds spinal task autonomy confined to a few research systems. Its authors class current robots as surgeon-controlled enabling technologies.
— Supervised autonomous debridement on the dVRK reached 93% success at 304 fragments/hour across 100 physical trials, beating the VLA baselines. The evidence is lab-only and self-reported.
171 more · latest 2026-08-31 →
— Negative: this review finds that every control layer for autonomous image-guided seed placement has advanced, but none has reached the threshold for clinical deployment.
— Audits Intuitive's five-layer AI roadmap against shipping reality: intraoperative guidance unfiled, augmented dexterity undeployed, supervised autonomy unannounced. Distinguishes roadmap vision from shipped production capability.
— Competitive landscape analysis: Intuitive maintains 11,710 installed systems; J&J OTTAVA FDA De Novo (July 22); Medtronic Hugo commercial launch; MicroPort Toumai overtook da Vinci in China unit share—'2026 is first year monopoly contested by opponents with real capability.'
— Tuodao Medical's Tuoling system completed 3 human surgical cases remotely with force-feedback over 2,400 km. Demonstrates haptic feedback transition from lab to human surgery, establishing force sensing as data source for AI training.
— FDA Digital Health Center proposed two-axis risk framework (clinical significance × autonomy level) for GenAI surgical systems with competency-based premarket evaluation, addressing semi-autonomous surgical autonomy regulation.
— Catalonia regional adoption surge: 9,402 robotic surgeries in 2025 (sevenfold increase from 1,288 in 2018), 24 hospitals participating, joint procurement achieving 21% cost reduction ($3.5M savings on €12.4M investment).
— University of Leeds research lab developing shared autonomy in surgical robots using computer vision and machine learning. Peer-reviewed publications through 2026 on autonomous tissue manipulation and retraction with cadaver validation.
— Systematic review of all FDA-cleared AI/ML devices: only 0.2% (3 of 1,357) evaluated patient-centered outcomes like mortality or readmissions. Reveals validation gap and maturity barriers for surgical AI systems despite regulatory approval.
— Analyzes 2026 market landscape covering cleared systems (OTTAVA De Novo, Hugo commercial launch) and research autonomy (Johns Hopkins SRT-H). Includes negative signal of Vicarious Surgical liquidation, revealing capital runway constraints on autonomy development.
— Profound Medical deploys real-time iMRI software upgrade to TULSA-PRO prostate ablation platform with 'supervised robotic autonomy.' Active deployment: 4 procedures/day (current), roadmap to 6/day. FDA-cleared US + 6 international markets.
— UK regulatory sandbox program with £3.6M funding and active multi-phase structure (Phases 1-2 completed, Phase 3 in design). Demonstrates regulatory preparation for AI-enabled surgical devices including autonomy management and adaptive systems.
— Intuitive revised 2026 guidance to 13.5-15.5% procedure growth; OTTAVA FDA De Novo July 22. Safety signal: 43% of FDA-authorized AI-enabled medical devices recalled <1 year (vs ~20% non-AI), reflecting validation and reliability barriers.
— China's regulatory shift from approval-focused to clinical-value assessment. MicroPort Toumai SP deployment at Peking University Shougang Hospital with structured training programs. Signals commercialization maturity and mainstream adoption pathway.
— Peer-reviewed perspective from Johns Hopkins: documents capital cost barriers ($2M system, $3-5K per case consumables) restricting adoption to high-income settings; global installed base shows 6,087 US vs 541 rest-of-world, revealing equity constraints on semi-autonomous deployment.
— Clinician critical assessment: robotic and manual microsurgery procedures achieve comparable clinical outcomes; identifies current maturity limitation—outcome parity despite technical sophistication—constraining clinical utility argument for autonomous microsurgery.
— Demonstrates dual-arm VLA model adaptive execution control on da Vinci-like hardware with measured success-rate improvements: 55%→60% needle manipulation, 55%→80% tissue manipulation, establishing necessity of adaptive execution for reliable surgical robotics deployment.
— Cites 2024 FDA systematic review: 86% of cleared surgical robots remain at Level 1 (continuous surgeon control), only 6% at Level 3 (conditional autonomy), documenting critical gap between marketing claims and regulatory-cleared autonomous capabilities.
— npj Digital Medicine perspective by leading AI researchers proposing staged embodied AI deployment: perioperative tasks first, high-risk surgical maneuvers last—providing critical governance framework cautioning against premature autonomy despite technical capability.
— Demonstrates real-time AI-enabled laparoscopic depth perception at 26 Hz with 3.7mm MAE accuracy, enabling enabling technology for autonomous scene understanding and manipulation critical to semi-autonomous laparoscopic procedures.
— Documented fatal medical accident: patient died from robotic-assisted prostatectomy vascular perforation (2022), highlighting concrete safety risks in surgeon-operated systems and postoperative decision-making failures informing autonomous system liability frameworks.
— Series A funding ($15M, $30M total) for Beacon semi-autonomous HoLEP platform with active ASTRA clinical trial recruiting 54 patients across 3 sites (Chile/NZ), demonstrating venture capital commitment to autonomous prostate surgery with defined pathway.
— UC San Diego preclinical feasibility study with teleoperated humanoid robots performing laparoscopic gallbladder removal; independent trade-press explicitly notes latency issues, multiple recalibrations, and longer procedure times constraining practical surgical application.
— Market research valuating fully autonomous surgical robotics at $5.2B (2025) projected to $47.8B (2034) at 28.5% CAGR, identifying FDA/EMA regulatory pathway acceleration as maturity signal supporting ecosystem expansion.
— Johns Hopkins SRT-H system performs independent autonomous surgical task execution (gallbladder removal phase) using transformer-based ML; research demonstrates progress in procedural autonomy scalability beyond isolated task demonstrations.
— DEPLOY Registry: verified database tracking 47 companies, 55 surgical robot models, and 52 commercial deployments with 24 documented safety incidents, providing verified ecosystem breadth and critical safety signal balance.
— Endorobotics' ROBOPERA obtains FDA 510(k) approval for endoscopic surgical automation, demonstrating ecosystem expansion beyond da Vinci into endoscopic semi-autonomous suturing with major vendor partnership (Olympus global exclusivity).
— Moon Surgical CEO reports SRS 2026 peer-reviewed data on Maestro: laparoscopic sleeve gastrectomy achieving significant reduction in procedural time variability and duration, advancing clinical evidence base for semi-autonomous surgical assistance.
— Critical analysis of Vicarious Surgical's $300M pre-clinical failure (zero patients) contrasts with OTTAVA's market-validated approach; documents innovation portfolio risk and commercialization barriers constraining autonomous surgical robotics scaling despite technical feasibility.
— KARL STORZ partnership signals ecosystem shift toward open surgical robotics platforms with AI-native workflow automation; market projection $9.1B (2026) → $20.8B (2034) at 10.9% CAGR reflects semi-autonomous systems as fastest-growing segment.
— Independent analyst quantifies Maestro semi-autonomous deployment: 4 procedures/week in French ambulatory settings, demonstrating market niche convergence toward high-volume predictable procedures as primary semi-autonomous use case.
— Medtronic's real-time AI compute platform (NVIDIA Holoscan infrastructure) establishes vendor infrastructure for autonomous surgical functions; first FDA-cleared application is decision-support, positioning foundation for autonomous capability evolution.
— Market penetration barrier documented: fewer than 10% of emerging-market hospitals can afford advanced robotic platforms at current price; capital constraints constraining adoption trajectory despite ecosystem maturation in developed markets.
— Critical negative signal: GLP-1 medications driving high single-digit decline in da Vinci bariatric procedures (Q2 2026); structural market headwind from pharmaceutical alternatives reducing procedure demand despite new vendor ecosystem entry.
— Market analysis documents competitive tier entry (Medtronic Hugo, CMR Versius Plus, J&J Ottava, Moon Surgical); projections $13.69B (2025) → $27.14B (2030); AI segment growing 17.8% annually signaling ecosystem maturation beyond Intuitive monopoly.
— Official HHS position from 7,000+ public comments: governance and trust infrastructure, not regulatory speed or technology maturity, are primary adoption barriers for AI-enabled surgical systems including semi-autonomous robotics.
— Peer-reviewed IEEE Robotics and Automation Letters: solves critical kinematic uncertainty for RCM surgical manipulators enabling autonomous subtasks (suturing, blood suction, tumor resection), directly enabling reliable autonomous surgical task execution.
— Johns Hopkins autonomous surgical robotics milestone: humanoid robots made 180 micro-decisions per minute, autonomously applied cautery to control arterial bleeding, demonstrating genuine adaptive autonomous capability and regulatory pathway (IDE application Q4 2026).
— Critical negative signal: UC San Diego humanoid platform (Unitree G1) flagged as Chinese military company (June 2026), carries wormable security exploit, transmits sensor data to China—concrete geopolitical adoption barriers extending regulatory/clinical pathway.
— Nature publication documenting teleoperated humanoid robots (Unitree G1) performing live laparoscopic cholecystectomy on porcine models with feasibility comparison to da Vinci standards, advancing general-purpose platform viability for surgical deployment.
— Ecosystem maturity assessment: 4 independent research groups and 3 medical vendors fielding working AI copilot prototypes; 35% of new surgical robot installations now AI-enabled; competitive fragmentation away from da Vinci monopoly signaling market transition.
— Large national cohort (N=949,507) showing robotic-assisted bariatric surgery associated with higher 30-day serious adverse event risk than conventional laparoscopy, critical negative signal for platform safety maturity constraining semi-autonomous feature integration.
— CMS formally established reimbursement pathway for algorithm-driven clinical care, removing identified economic barrier to semi-autonomous surgical procedure adoption and payment infrastructure gap constraining market expansion.
— CE marking regulatory approval for Shanghai MicroPort MedBot's Toumai system with named landmark clinical procedure: remote prostatectomy from London to Gibraltar (March 2026), demonstrating ecosystem diversification beyond incumbent vendors into semi-autonomous remote operation.
— In-depth technical analysis of Johns Hopkins SRT-H system achieving 100% success on clipping-and-cutting phase of laparoscopic cholecystectomy across 8 ex vivo specimens with step-level autonomy, explicit about gaps (ex vivo tissue, single phase, unresolved liability/regulation).
— FDA 510(k) clearance for LEM Surgical Dynamis dual-arm humanoid architecture with continuous independent vertebra tracking and bilateral workflow, signaling second major vendor achieving approval for hard-tissue autonomous navigation and stabilization.
— Peer-reviewed ICRA 2026 paper addresses foundational technical barrier—kinematic inaccuracies in surgical robots—through learned visual feedback policy, demonstrating sim-to-real transfer on da Vinci Research Kit for robust autonomous control methodology.
— Critical review explicitly stating 'No system currently performs autonomous surgery without direct human oversight' and autonomy claims are 'limited to research environments,' providing essential negative signal about current state of semi-autonomous deployment readiness.
— Critical research documenting vulnerability of end-to-end learned surgical policies to adversarial attacks, with 61% success-rate reduction on debridement and suturing subtasks, revealing robustness limitations in safety-critical semi-autonomous execution.
— SAGES professional-society white paper identifying inadequate regulatory and legal frameworks for AI-assisted surgery, proposing tripartite risk framework (AI system, clinician, institutional risks) and calling for robust governance—evidence of maturity barriers.
— Identifies critical infrastructure gap: only 3% of surgical platforms offer conditional decision-making despite high-fidelity intraoperative data availability; lacking standardized data ontology and interoperability standards constrains autonomous task execution scaling.
— South Korea's Ministry of Food and Drug Safety formalized regulatory approval framework for semi-autonomous surgical robots (autonomous bone cutting, screw insertion) effective December 2025, directly advancing regulatory infrastructure for autonomous surgical deployment.
— NVIDIA Isaac platform enables software-in-the-loop and hardware-in-the-loop simulation of autonomous surgical robots with digital twins prior to clinical trials, demonstrating maturation of development and validation infrastructure for semi-autonomous surgery.
— Practitioner-grounded cybersecurity architecture framework for multi-vendor integrated surgical robots achieved 73% residual risk reduction; demonstrates engineering maturity and safety infrastructure required for autonomous surgical system deployment.
— JAMA Surgery analysis of Medicare beneficiaries 2020–2023 documents robotic-assisted adoption growth alongside higher bile duct injury risk vs laparoscopic approach—critical negative signal on outcomes despite platform expansion.
— Peer-reviewed benchmark of imitation learning policies for autonomous robotic suturing achieved 92% stitch completion in real surgeon-robot trials, demonstrating feasibility of semi-autonomous procedure execution in open surgery.
— Systematic review reveals utilities recognized in 13.2 months vs operational issues emerging after 26.0 months during device adoption, explaining why evidence sets appear skewed toward benefits early in semi-autonomous technology maturation cycles.
— JASPER (ForSight Robotics) achieved world-first fully robot-assisted cataract surgery in human (2026), extending semi-autonomous surgical execution beyond traditional surgical domains into ophthalmology.
— Class I recalls of da Vinci systems (incomplete staple lines, arm screw breakage) documented May 2026 raise critical product reliability concerns, regulatory scrutiny, and adoption barriers during escalating autonomous feature integration.
— Royal College of Surgeons Ireland governance framework recommends AI deployment as support tool in human-in-the-loop model, establishing institutional consensus on supervised autonomy and embedding AI in surgical education as prerequisites for safe adoption.
— IndexBox market analysis explicitly identifies AI integration for procedural planning and intraoperative guidance as primary demand driver for surgical robotics market growth, showing analyst-level recognition of semi-autonomous surgery as market transformation.
— Chinese Shuairu robot CE-marked and deployed at Munich Klinik Bogenhausen (May 2026), first DAcH region deployment; documented cases show single-port lung resection and adrenal resection with acceptable outcomes, breaking US monopoly in premium surgical robotics in Europe.
— Prospective study at Stanford and European centres: 79 Maestro-assisted vs 79 conventional laparoscopic cholecystectomies showed 35% reduction in operative time variability with no device-related complications, validating semi-autonomous surgical assistance in production clinical setting.
— FORTE study: J&J OTTAVA completed 30-patient gastric-bypass trial with 100% procedures completed autonomously without conversion to manual surgery, met primary safety/performance endpoints, and filed FDA De Novo application for multi-procedure general surgery, signaling second major vendor entry into semi-autonomous surgical deployment.
— Liverpool, Madrid, and Italian surgeons provide critical practitioner assessment: surgical AI deployment lacks evidence prospective validation, ethical safeguards against automation bias, and equity protection against dataset bias—identifying governance gaps limiting safe semi-autonomous surgical deployment.
— Hugo RAS platform deployed across 30+ countries with tens of thousands of procedures; Asan Medical Center (Seoul, major academic institution) partnership signals institutional recognition at leading-edge centres and geographic diversification beyond US market.
— Learning-based adaptive control for autonomous tissue retraction with zero-shot generalization across similar tasks; real-world experiments on deformable materials accepted to RSS 2026, demonstrating technical progress in autonomous surgical subtask execution.
— King's College London analysis identifies 'embodied AI' regulatory blind spot: how regulators manage systems that learn and evolve post-approval, prevent dataset bias reinforcing healthcare inequalities, and address global research/industry concentration imbalances remain unresolved governance challenges.
— Stanford, UCLA, Johns Hopkins framework for translating AI/ML into surgical robotics autonomy identifies critical evidentiary gaps—limited data on generalization across institutions and clinical utility under routine conditions—emphasizing need for safety assurance coupling algorithmic performance with human-system interaction.
— Industry analyst assessment of autonomous surgical robotics barriers: surgeon acceptance of autonomous execution differs from guidance; regulatory caution around autonomy near neural structures; liability frameworks undefined—concluding that supervised autonomy (surgeon defines strategy, monitors execution, intervenes when needed) is most realistic near-term model.
— National cohort study of 185,000+ robotic general surgery cases: surgeon's annual case volume is critical outcome determinant, informing credentialing standards and safe scaling pathways for semi-autonomous surgical capabilities across institutions.
— King's College London experts forecast surgical robotics shift toward autonomous systems with human-in-the-loop control, embodied AI, and autonomous surgical assistance—establishing the technical trajectory for semi-autonomous procedure adoption.
— Johns Hopkins expert H. Russell Taylor frames core challenges delimiting feasible semi-autonomous surgery scope: specifying clinical intent to autonomous systems and ensuring safe execution within defined constraints; proposes hybrid approaches combining AI with patient-specific digital twins.
— Irish HPRA (regulatory authority) issued device modification guidance for da Vinci X & Xi systems in April 2026, documenting ongoing operational/safety concerns affecting deployed installed base and constraining autonomous feature integration.
— Q1 2026: da Vinci procedures grew 16% to 847K cases, Ion surged 39% to 43K cases; management raised 2026 guidance to 14-16% da Vinci growth, though China policy uncertainty and GLP-1 drug competition signal market headwinds.
— Analyst intelligence documents multiple Class II FDA recalls of da Vinci reusable instruments (broken pitch cables across monopolar scissors, graspers, drivers, hooks, forceps) with worldwide distribution and ongoing status, signaling systemic quality concerns in deployed base.
— Peer-reviewed analysis of autonomy classification systems and governance frameworks for autonomous surgical robots; proposes mechanisms for responsibility attribution, algorithm transparency, and safety monitoring as prerequisites for responsible innovation.
— FDA clearance of Moon Surgical's ScoPilot—AI-driven autonomous camera positioning on Maestro platform. First FDA-cleared AI intraoperative function running natively on commercial surgical robotics, deployed across 1,100+ patients.
— Market analysis projecting microsurgery robot market at 17.12% CAGR for semi-autonomous systems (fastest-growing segment) through 2031. Documents 900+ clinical cases in Europe; semi-autonomous systems reducing proficiency curve from 40 manual cases to 15 cases.
— World-first deployment of Medtronic Stealth AXiS with LiveAlign real-time autonomous vertebral tracking maintaining robotic alignment throughout spine procedures. Complex multi-level fusion with AI-integrated surgical planning and continuous segmental navigation.
— FDA alert documenting da Vinci curved-tip stapler failures with incomplete staple line formation on blood vessels, causing 4 serious injuries and 1 death by February 2026. Critical safety barrier constraining surgical robotics platform deployment.
— Practicing surgeon's critical technical analysis of Johns Hopkins SRT-H system, separating realistic capabilities from media hype about autonomous procedures and assessing near-term clinical implications of autonomous surgical robotics.
— King's College London position statement establishing international consensus standards for semi-autonomous robotic mechanical thrombectomy navigation. Notes AI-assisted MT robotics 'not yet ready for routine clinical use' despite hardware-level autonomy demonstration.
— FDA 510(k) clearance for Moon Surgical's Maestro System with ML-based surgical instrument detection and tracking. Class II medical device for laparoscopic procedure support with motorized arms and autonomous position maintenance.
— Patent landscape analysis of 70+ records (2011–2026) documenting ecosystem-wide R&D maturation: foundational (2011–2017), rapid scale-up (2018–2021), AI integration (2022–2024), and autonomous execution frontier (2025–2026) with consistent master-slave/cooperative-control architecture.
— Chinese clinical trial registry documenting MP1000/MP2000 systems approved by NMPA with 100% success rate across urology, gynecology, general, and thoracic surgeries. Edge Cloud remote surgery system NMPA-approved November 2025, signaling competing vendor ecosystem.
— Maestro semi-autonomous system progression: 50 first-in-human procedures (2022), FDA clearance (Dec 2022), CE mark (Apr 2023), 200 EU commercial procedures (Apr 2024), commercial FDA clearance (Jun 2024), demonstrating rapid scaling from clinical trials to multi-site deployment.
— National Academy of Sciences Distinctive Voices lecture explicitly states 'autonomous surgery is no longer science fiction' and that 'semi-autonomous robots perform surgery,' representing institutional mainstream recognition of field maturation.
— FDA early alert on da Vinci SureForm 30 stapler malfunction causing incomplete staple formation with 4 injuries and 1 death reported as of Feb 2026, demonstrating critical safety barriers in production deployment independent of autonomous functionality.
— Novel ML framework for autonomous surgical suturing trajectory prediction trained on 1,158 trajectories from 50 patients showing 58.6% error reduction over baselines, demonstrating practical progress in core semi-autonomous task execution.
— Seger Surgical's first-in-human semi-autonomous intracorporeal anastomosis device completed 3 successful procedures with 100% success rate and <2 minute closure time versus 15-20 minutes manual, demonstrating emerging commercial deployments beyond Moon Surgical Maestro.
— Critical analysis documenting 14-fold increase in adverse events after AI integration in surgical guidance systems (Acclarent case study) and revealing that <2% of 1,357 FDA-authorized AI-enabled medical devices had supporting randomized trials, exposing regulatory and safety barriers.
— Health journalism synthesis covering autonomous examples: SRT-H 100% accuracy on 8 ex vivo procedures, Chile autonomous camera control during solo gallbladder removal, Hong Kong 3-hand system clipping blood vessels, and meta-analysis showing 25% OR time reduction and 30% complication decrease.
— CHU de Rouen became first French university hospital to adopt Maestro semi-autonomous system (February 3, 2026), demonstrating expansion of dedicated semi-autonomous platforms beyond commercial pilots into major teaching institutions.
— Investigative journalism documenting 12,000+ robotic surgeries and 800 remote 5G-enabled surgeries in China with real-world adoption barriers: automation bias, patient/family uncertainty, and physician struggle with deferred decision-making in ostensibly autonomous systems.
— CHU de Rouen became first French university hospital to adopt Moon Surgical's Maestro semi-autonomous system, with first procedure on February 3, 2026—demonstrating institutional adoption expanding across European teaching hospitals.
— Class II FDA recall issued February 2026 for da Vinci 5 console assembly software configuration issues, demonstrating ongoing reliability concerns impacting facility workflows and constraining platform adoption momentum.
— Northeastern University medical device safety group petitioned FDA for immediate Class I recall of da Vinci 5 due to intraoperative power failures, highlighting unresolved platform reliability barriers constraining autonomous deployment.
— American College of Surgeons bulletin documents global robotic surgery adoption at 5% of US procedures, 2% in Europe, advancing institutional integration of AI-enabled robotic platforms across geographies.
— Intuitive Surgical cancelled MOU with Surgical Science for software integration into da Vinci 5 platforms, reverting to selective deployment—signaling strategic shift in ecosystem maturation and adoption velocity constraints.
— Editorial in Journal of Arthroplasty argues for enduring surgeon role amid automation, providing critical perspective on limits of autonomous systems despite technical advances.
— FDA 510(k) clearance for da Vinci 5 expanded to cardiac indications (valve repair, ASP closure, IMA mobilization, etc.), expanding mainstream platform applicability and infrastructure for semi-autonomous feature integration.
— IDEAL 2a multi-center observational study of Moon Surgical's Maestro semi-autonomous platform for solo abdominal surgery across 45 procedures—zero device-related adverse events with 40% procedure conversion rate and robust safety profile.
— Q4 2025 earnings report showing 1,200 da Vinci 5 systems installed globally, 270,000 procedures performed, and 11% higher utilization than Xi model—confirming accelerated adoption of AI-enabled mainstream surgical robotics platform.
— CEO interview reporting Maestro semi-autonomous platform deployed in 2,200+ patients worldwide with FDA clearance for iterative AI updates (March 2025), advancing commercial scale beyond initial clinical trials.
— American College of Surgeons bulletin article discussing AI integration in surgery, citing autonomous gallbladder removal (July 2025) and intercontinental robotic cardiac telesurgery as pivotal advancements while raising governance questions.
— December 2025 regulatory updates: Class 2 FDA recall (144 units) for da Vinci 5 Surgeon Console connector issue and FDA expansion of da Vinci SP to general surgery (hernia, cholecystectomy, appendectomy), providing simultaneous signals of reliability concerns and procedure category expansion.
— Peer-reviewed commentary references SRT-H system achieving 100% autonomous cholecystectomy task success but argues that technical advancement doesn't guarantee clinical readiness; emphasizes human factors, situational awareness gaps, and practical barriers constraining autonomous deployment despite capability breakthroughs.
— Huntsman Cancer Institute's production-scale da Vinci 5 deployment: 10 platforms across 5 operating sites with 44 active surgeons, 12,000+ cumulative procedures since 2005, and 40% reduction in tissue force applied—demonstrating real-world clinical adoption of latest AI-enabled platform.
— Q3 2025 earnings show 240 da Vinci 5 placements (up from 110 in Q3 2024, 118% growth) and 427 total da Vinci placements with 20% procedure growth year-over-year, confirming rapid market adoption of latest AI-enabled robotic surgical platform during Q4 window.
— Market analysis shows 10,189 da Vinci systems installed (15% YoY growth), da Vinci 5 with 2,500+ surgeons using it for 32,000+ procedures and 147 systems placed in Q1 2025, positioning platform for autonomous feature integration; company actively exploring future AI applications including autonomous suturing.
— Surgical Science signed letter of intent to integrate simulation software into all da Vinci 5 systems via subscription-based model (effective Jan 2025), signaling ecosystem maturation and standardization of training infrastructure supporting broader surgical robotics adoption.
— NeurIPS 2025 benchmark for autonomous suturing with released dataset of 1,890 demonstrations; goal-conditioned framework improves targeting accuracy 59-74% over baseline, advancing precision in autonomous suturing research.
— Systematic review (32 studies) accepted at 2025 IEEE ROMAN conference; identifies growing ASAR research emphasis, current strength in endoscope guidance, emerging tool manipulation advances, and persistent challenges in procedural awareness and human-robot coordination.
— Johns Hopkins/Stanford SRT-H AI system successfully performed 8 ex vivo gallbladder removal procedures with 100% accuracy autonomously, demonstrating shift from task-specific execution to procedural understanding; published in Science Robotics.
— Critical expert commentary on SRT-H gallbladder study emphasizes biological variability, testing on young animals without patient comorbidities, and cost barriers; reflects skepticism about near-term clinical deployment despite technical proof-of-concept.
— Updated UCSD pipeline for autonomous suturing using reliability-driven thread reconstruction with >400 grasping trials; demonstrates state-of-the-art accuracy for autonomous suture manipulation independent of tissue properties.
— Moon Surgical reports Maestro semi-autonomous system deployed in 1,600+ procedures worldwide with 1,400 in past year across 60 surgical types, demonstrating rapid acceleration of dedicated semi-autonomous platform adoption in Q2 2025.
— Moon Surgical CEO interview confirms Maestro semi-autonomous system used in 60+ patients in U.S. and Europe, second-generation deployed in France with AI integration for setup automation and vision control advancing commercial deployment.
— Translational study of semi-autonomous robotic system for dental implant placement across models, animals, and 60 human participants demonstrated significantly lower angular deviation (3.1° vs 7.9°, p<.001) and superior accuracy with zero complications.
— Industry analysis projects global autonomous surgical robotics market to exceed €10 billion by 2033; identifies regulatory frameworks as primary bottleneck and emphasizes that AI maturation is accelerating progress toward autonomous surgery implementation.
— Academic review identifies inadequate regulatory frameworks, liability ambiguity, and missing informed consent standards as critical barriers to autonomous robotic surgery deployment, reinforcing governance challenges constraining adoption beyond research settings.
— Reinforcement learning framework for autonomous robotic suturing with 3D vision achieved higher accuracy than teleoperation on synthetic tissue models, advancing autonomous suturing feasibility through improved trajectory optimization and tissue deformation handling.
— Class 2 FDA recall of da Vinci 5 (faulty foot pedal, 439 units affected) revealed platform-level reliability issues mid-2025 rollout, reinforcing safety and liability barriers constraining adoption of autonomous features despite technical advances.
— Market analysis shows da Vinci 5 launch exceeding expectations with 2,500+ surgeons, 40+ procedure types, and 493 units placed in Q4 2024, demonstrating broad platform adoption creating foundation for autonomous feature integration at scale.
— Vision-language model integrated with da Vinci robot achieved zero-shot imitation learning from 20 hours of surgical video, autonomously performing tissue lifting, needle use, and suturing with problem-solving capability, advancing practical autonomous surgical task execution.
— Moon Surgical reports successful completion of first-in-human clinical study with 30 laparoscopic procedures using Maestro semi-autonomous system at CHU Saint-Pierre teaching hospital, validating clinical safety and efficacy of dedicated semi-autonomous platform.
— Johns Hopkins demonstrates imitation learning training surgical robots from video of seasoned surgeons, achieving human-equivalent performance on complex procedures—eliminating manual programming and advancing true autonomy where robots perform surgeries without human help.
— Johns Hopkins robotics panel acknowledges AI advances toward autonomous surgery but emphasizes complementary human-machine capabilities and surgeon oversight, reflecting expert consensus that partnership rather than full replacement remains realistic near-term pathway.
— Market analysis documents regulatory divergence between FDA's SaMD pathway and EU Medical Device Regulation for AI-enabled surgical robots, identifying harmonization barriers and post-market surveillance requirements constraining international autonomous system deployment.
— ARPA-H awards up to $12M to multi-institution consortium (Vanderbilt, Utah, Johns Hopkins) for developing fully autonomous surgical robot for tumor removal with 3-year demonstration goal in simulated conditions, signaling major institutional commitment to autonomous surgery development.
— Research demonstrates autonomous data-driven robotic needle steering for MRI-guided prostate procedures using parameter-agnostic trajectory correction and closed-loop shape sensing, advancing autonomous execution in critical clinical tasks.
— Research from UC San Diego presents autonomous image-to-grasp robotic suturing pipeline with over 400 grasping trials demonstrating state-of-the-art accuracy for autonomous suture thread manipulation and grasping, advancing feasibility of core autonomous surgical subtask.
— ICRA 2024 full-day workshop convened leading experts to address regulatory frameworks (EU AI Act), technical integration pathways, and clinical roadmaps for autonomous surgical robots, reflecting mainstream academic and industry engagement with autonomy implementation challenges.
— Analysis of Intuitive Surgical's Q2 2024 AI patenting strategy shows focus on autonomous determination of surgical procedure stages with context-relevant assistance, demonstrating market leader R&D investment in autonomy features for mainstream robotic platforms.
— Surgical Robotics Industry Awards highlight Moon Surgical's Maestro System in commercial use across multiple hospitals with 250+ patients treated, and MMI's Symani System receiving FDA De Novo clearance (April 2024) for reconstructive microsurgery, demonstrating market advancement in semi-autonomous and precision robotics.
— Surgical Endoscopy review of 41 autonomous suturing articles (81% post-2014) found significant technological advances in knot-tying and needle insertion subtasks, with 76% of research in engineering journals, confirming sustained academic interest and feasibility progress in autonomous suturing.
— NPJ Digital Medicine systematic review of 49 FDA-cleared surgical robots (2015-2023) found 86% at Level 1 autonomy, 6% at Level 3, and only 2 with ML-enabled capabilities, revealing regulatory frameworks lag technical autonomy trends and identifying gaps in formal autonomy classification.
— Legal analysis identifies mechanical failures (arm calibration, instrument failure), software glitches, and programming errors as common robotic surgery complications, noting that surgeon expertise is critical to anticipating and mitigating system failures—highlighting ongoing reliability risks.
— Moon Surgical reports Maestro semi-autonomous laparoscopic system in commercial use across 2 French hospitals with 200+ patients treated by 10+ surgeons, demonstrating scale-up from clinical trial to multi-site deployment with AI-powered ScoPilot autonomy.
— SEC 8-K filing documents FDA 510(k) clearance of da Vinci 5 with >10,000x computing power of Xi enabling AI integration, force feedback reducing tissue trauma by 43%, and autonomy features advancing semi-autonomous deployment.
— Tampa Bay Times reports federal lawsuit alleging da Vinci robot caused fatal injury via electrical arc during colon surgery, highlighting platform safety risks and liability concerns that constrain autonomous system adoption and surgeon acceptance.
— Purdue University study evaluates mental workload-based adaptive automation for semi-autonomous suction assistance, achieving 77.9% workload classification accuracy and demonstrating feasibility of reducing surgeon cognitive load.
— Johns Hopkins STAR robot demonstrates single-arm autonomous suturing with suture management at 29.1 seconds per stitch, advancing toward autonomous anastomosis by reducing system complexity from dual-arm to single-arm architecture.
— Intuitive Surgical 2023 adoption metrics show 14 million cumulative da Vinci procedures (22% growth in 2023), over 9,100 installed systems, and >2.2 million procedures annually, confirming sustained platform adoption underpinning semi-autonomous integration efforts.
— Georgia Tech MICCAI 2023 workshop paper demonstrates demonstration-guided reinforcement learning for autonomous soft tissue retraction on da Vinci in simulation, validating feasibility of autonomous exposure task.
— UC Berkeley/CASE 2023 paper presents self-supervised learning for autonomous suture tail-shortening with 90% success rate across 20 trials, advancing autonomous thread manipulation as key surgical subtask.
— IEEE Robotics and Automation Letters study shows STAR robot achieves superior vaginal cuff closure accuracy and consistency versus human surgeons on synthetic tissue, advancing autonomous execution of complete surgical procedures.
— Moon Surgical's Maestro semi-autonomous laparoscopic system achieved CE Mark regulatory approval with 50-patient clinical trial in Europe, demonstrating clinical-stage deployment of semi-autonomous surgical assistance technology.
— German regulatory agency safety notice on da Vinci surgical systems indicates platform-level device safety issues and corrective actions, reinforcing reliability barriers that constrain autonomous system integration and adoption.
— Randomized controlled preclinical trial in Annals of Surgical Oncology shows new robotic system achieves statistically significant improvements in suture precision (p=0.02 distance, p<0.01 angulation) versus manual techniques, advancing microsurgical capability.
— Academic research framework for autonomous suturing ranked first in AccelNet Surgical Robotics Challenge, demonstrating algorithmic progress in needle pose estimation and trajectory planning for autonomous surgical tasks.
— Systematic review in Artificial Intelligence Surgery identifies technical, ethical, and clinical barriers to autonomous surgery including high computational requirements, annotated data scarcity, and surgeon knowledge gaps in AI concepts.
— iRobotSurgeon survey of 2,191 respondents across 78 countries reveals liability and blame allocation barriers: participants blame surgeons less as robotic autonomy increases, yet still assign blame in fully autonomous scenarios, highlighting regulatory uncertainties.
— Johns Hopkins review in Proceedings of the IEEE surveys autonomy trends in surgical robotics, noting over 4,000 telerobots in daily use and research focus on introducing surgeon-assist autonomy to reduce tedium and improve consistency.
— Expert consensus definitions from Artificial Intelligence Surgery journal establish standardized terminology for AI and autonomy in surgery, signaling community maturation as autonomous systems develop.
— Legal analysis of malpractice claims in robotic surgery identifies significant liability and safety barriers that inform regulatory risk for autonomous systems, constraining adoption trajectory.
— Systematic review of 51 articles confirms that while fully automated systems remain conceptual, supervised autonomous robotic systems are actively researched but face significant ethico-legal hurdles.
— Purdue research demonstrates semi-autonomous suction assistance using EEG-based cognitive workload assessment, showing 80% accuracy in detecting surgeon demand states and potential for improved collaboration.
— Analysis of 679 da Vinci robot malfunction reports shows 84.5% instrument malfunction rates and 15.6% patient injury rates, revealing critical platform reliability and safety gaps that constrain autonomous system adoption.
— Johns Hopkins STAR robot autonomously performed intestinal anastomosis on pig tissues with superior results to human surgeons, demonstrating a significant step toward fully automated surgery.
— Johns Hopkins and Stanford research demonstrates imitation learning enabling autonomous surgical tasks on da Vinci platform—tissue manipulation, needle handling, knot-tying—advancing ML-driven autonomous surgical capabilities.
— Analysis of 35 AI publications finds low quality evidence and small datasets; concludes there is no proof AI can identify critical tasks determining patient outcomes, revealing maturity gaps in AI-assisted surgical systems.
— Critical review from UT Southwestern argues for collaborative enhancement over full autonomy, noting research found no studies evaluating semi-autonomy effects on patient outcomes, highlighting evidence gaps.
— First in vivo autonomous robotic laparoscopic surgery via intestinal anastomosis on porcine models, achieving level 3 autonomy with superior consistency and accuracy compared to human surgeons and manual laparoscopic techniques.
— Clinical trial registration indicating planned human clinical evaluation of semi-autonomous surgical systems for cardiac interventions, marking progression from preclinical research to human testing.
— Review article notes that while fully autonomous systems remain distant, partially autonomous systems have gradually entered clinical use, with investments from Intuitive Surgical, Google, Verb Surgical, and others.
— Nature Reviews Urology reports first clinical trial data on autonomous robotic-assisted surgery in urology being published, marking the emergence of autonomous surgical capabilities from preclinical research into clinical evaluation.
— IEEE paper presents semi-autonomous tissue retraction using deep neural networks and procedural algorithms, achieving 25% visibility improvement on DaVinci Research Kit, demonstrating progress toward autonomous execution of fundamental surgical tasks.
— Survey of 508 surgeons shows 83.3% willing to adopt AI-based autonomous surgical assistant systems and 40% believe such systems could substitute 41-60% of current workforce, indicating strong clinical interest in autonomous surgical capabilities.
— Comprehensive review in Surgical Clinics of North America documenting complications across robotic-assisted procedures, showing that despite revolutionary impact, systems are 'not exempt from complications,' providing critical assessment of maturity challenges.
— ICRA 2020 paper demonstrates autonomous suturing system achieving 0.27mm accuracy in tissue phantoms using deep learning-based tissue detection and path planning, advancing technical feasibility of autonomous micro-surgical tasks.